Abstract

N-Acetylaspartylglutamate (NAAG) is found at high concentrations in the vertebrate nervous system. NAAG is an agonist at group II metabotropic glutamate receptors. In addition to its role as a neuropeptide, a number of functions have been proposed for NAAG, including a role as a non-excitotoxic transport form of glutamate and a molecular water pump. We recently identified a NAAG synthetase (now renamed NAAG synthetase I, NAAGS-I), encoded by the ribosomal modification protein rimK-like family member B (Rimklb) gene, as a member of the ATP-grasp protein family. We show here that a structurally related protein, encoded by the ribosomal modification protein rimK-like family member A (Rimkla) gene, is another NAAG synthetase (NAAGS-II), which in addition, synthesizes the N-acetylated tripeptide N-acetylaspartylglutamylglutamate (NAAG(2)). In contrast, NAAG(2) synthetase activity was undetectable in cells expressing NAAGS-I. Furthermore, we demonstrate by mass spectrometry the presence of NAAG(2) in murine brain tissue and sciatic nerves. The highest concentrations of both, NAAG(2) and NAAG, were found in sciatic nerves, spinal cord, and the brain stem, in accordance with the expression level of NAAGS-II. To our knowledge the presence of NAAG(2) in the vertebrate nervous system has not been described before. The physiological role of NAAG(2), e.g. whether it acts as a neurotransmitter, remains to be determined.

Highlights

  • B, the amount of NAA, and peptides NAAG and X synthesized in CHO-K1 cells expressing NAAGS-II together with NaDC3, and in control cells, metabolically labeled with [14C]NAA for 16 h were quantified using a Bioimager

  • Mass spectrometry confirmed the presence of NAAG2 in the murine nervous system, where NAAG2 concentration correlates with the rimK-like family member A (Rimkla)/NAAGS-II expression level

  • Similar results were reported by Collard et al [29], who showed that the homologous gene Rimkla encodes a NAAG synthetase

Read more

Summary

Introduction

B, the amount of NAA, and peptides NAAG and X synthesized in CHO-K1 cells expressing NAAGS-II together with NaDC3, and in control cells, metabolically labeled with [14C]NAA for 16 h were quantified using a Bioimager. F, peptide extracts from NaDC3 and NAAGS-II coexpressing CHO-K1 cells metabolically labeled with [14C]NAA (as shown in panel A) were separated by TLC, in the presence (ϩNAAG2) or absence (ϪNAAG2) of synthetic NAAG2, and the distribution of radioactivity was determined using a Bioimager.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call